Epidemiology and results of the first line therapy for HIV-related Hodgkin lymphoma-Reference-Cited by-同舟云学术

Epidemiology and results of the first line therapy for HIV-related Hodgkin lymphoma

Published:2022-07-04 Issue:3 Volume:29 Page:65-73
ISSN:2541-8807
Container-title:The Scientific Notes of the Pavlov University
language:
Short-container-title:The Scientific Notes of the Pavlov university

Author:

Chekalov A. M.¹^ORCID,Popova M. O.¹^ORCID,Tsygankov I. V.¹,Rogacheva Yu. A.¹^ORCID,Volkov N. P.¹^ORCID,Lepik K. V.¹^ORCID,Demchenkova M. V.²,Schneider T. V.³,Kopeikina Yu. V.³,Medvedeva N. V.⁴,Zyuzgin I. S.⁵,Pavlyuchenko E. S.⁶,Levanov A. N.⁷,Myasnikov A. A.⁸,Kariagina E. V.⁹,Mikhailova N. B.¹,Baykov V. V.¹,Kulagin A. D.¹^ORCID

Affiliation:

1. Pavlov University

2. Irkutsk Regional Cancer Center

3. Leningrad Regional Clinical Hospital

4. Municipal clinical hospital № 31

5. National Medical Research Center of Oncology named after N.N. Petrov

6. North-Western State Medical University named after I. I. Mechnikov

7. Saratov State Medical University

8. V. A. Baranov Republican Hospital

9. City Hospital № 15

Abstract

Introduction. The risk of developing Hodgkin lymphoma (HL) with HIV infection is higher than in the general population, and the course of the disease itself is more aggressive. Currently, there is no unified approach to the treatment of HIV-related HL, and data on its epidemiology in the Russian Federation are limited.The objective was to study epidemiological characteristics, the used therapeutic tactics and the results of treatment for HIV-related HL.Methods and materials. The multicenter retrospective study included 46 patients with HIV- related HL treated in 9 centers of the Russian Federation. Descriptive statistics methods were used, the analysis of overall survival (OS) and progression-free survival (PFS) was performed using the Kaplan–Meier method.Results. HIV-related HL is more often represented by an advanced stage, B-symptoms, and extranodal lesions. The ABVD regimen was used as the first-line therapy in 60 % for HIV-related HL. The overall response to therapy was 81.6 %, and the 2-year OS and PFS were 85 % and 49 %, respectively. Factors that worsened OS were CD4+˂266 cells/mcL and general somatic status ECOG≥2.

Publisher

FSBEI HE I.P. Pavlov SPbSMU MOH Russia

Subject

Urology,Nephrology

Link

https://www.sci-notes.ru/jour/article/viewFile/910/pdf_290

Reference24 articles.

1. Silverberg M. J., Lau B., Achenbach C. J., Jing Y., Althoff K. N., D’Souza G., Engels E. A., Hessol N. A., Brooks J. T., BurchellA. N., Gill M.J., GoedertJ.J., Hogg R., Horberg M. A., Kirk G. D., Kitahata M. M., Korthuis P. T., Mathews W. C., MayorA., Dubrow R. Cumulative Incidence of CancerAmong PersonsWith HIV in NorthAmerica:ACohort Study //Annals of Internal Medicine. 2015;163(7):507– 518. Doi: https://doi.org/10.7326/M14-2768.

2. Powles T., Robinson D., Stebbing J., Shamash J., Nelson M., Gazzard B., Mandelia S., Møller H., Bower M. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection // Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2009;27(6):884–890. Doi: https://doi.org/10.1200/JCO.2008.19.6626.

3. Biggar R. J., Jaffe E. S., Goedert J. J., Chaturvedi A., Pfeiffer R., Engels E. A. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS // Blood. 2006; 108(12): 3786–3791. Doi: https://doi.org/10.1182/BLOOD2006-05-024109.

4. Carroll V., Garzino-Demo A. (2015). HIV-associated lymphoma in the era of combination antiretroviral therapy: shifting the immunological landscape // Pathogens and Disease. 2015;73(7). Doi: https://doi.org/10.1093/FEMSPD/FTV044.

5. GoedertJ.J., Bower M. (2012). Impact of highly effective antiretroviral therapy on the risk for Hodgkin lymphoma among people with human immunodeficiency virus infection // Current Opinion in Oncology. 2012;24(5):531–536. Doi: https://doi.org/10.1097/CCO.0B013E3283560697.